

Inflammation & Fibrosis Across Organs

March 12th, 2026

Felix Frey Auditorium, SITEM, Freiburgstrasse 3, 3010 Bern

Bringing together leading experts from research, clinics, and diverse medical fields, this congress aims to foster collaboration and enhance our understanding of fibrosis across organs.

Scientific Committee:

Prof. Dr. Sabina Guler, Dr. Mirjam Kolev, PD Dr. Florian Kollert, Dr. Adela-Cristina Sarbu


Register now for the event:



Supported by:



**Burgergemeinde
Bern**



Preliminary Program

08.00 – 08.15 **Registration with coffee**

08.15 – 08.30 Welcome, *Sabina Guler, Mirjam Kolev, Florian Kollert, Adela-Cristina Sarbu*

08.30 – 10.30 **Session I: Molecular Mechanisms of Fibrosis: Shared and Distinct Pathways Across Organs**

Chairs: Nasser Semmo, Bern;
Diego Kyburz, Basel

08.30 – 09.00 Fibroblast: Masterminds of Tissue Response to Inflammation, *Muriel Elhai, Zürich*

09.00 – 09.30 Synovial Fibroblasts in Rheumatoid Arthritis, *Christopher Buckley, Oxford*

09.30 – 10.00 Current and Emerging Therapies for Skin Manifestations in Systemic Sclerosis, *Oliver Distler, Zurich*

10.00 – 10.15 Discussion

10.15 – 10.45 **Break**

10.45 – 12.30 **Session II: Challenges in Diagnosis and Management of Fibrotic Diseases**

Chairs: Annalisa Berzigotti, Bern


10.45 – 11.15 Classification of Fibrotic Interstitial Lung Diseases, *Christopher Ryerson, Vancouver*

11.15 – 11.45 Liver Fibrosis: Different Etiologies, Cellular Mechanisms and the Potential for Regression, *Sara Lemoinne, Paris*

11.45 – 12.15 Understanding Chronic Periaortitis: Mechanisms and Management, *Augusto Vaglio, Parma*

12.15 – 12.30 Discussion

12.30 – 13.30 **Lunch Break**



13.30 – 15.00

**Session III: Fibrosis Treatment Today:
State of the Art and Emerging Strategies**

Chairs: Uli Walker, Basel; Guido Stirnimann, Bern

13.30 – 14.00

Current Treatment Strategies for Pulmonary Fibrosis,
Michael Kreuter, Mainz

14.00 – 14.30

Current and Future Treatment Options in Primary
Sclerosing Cholangitis, *Trine Folseraas, Oslo*

14.30 – 15.00

Entero-Nephro-Hepatic Circulation of Bile Acids in
Health and Disease: Role of Bile Acids in Cholemic
Nephropathy and Potential Therapies,
Ahmed Ghallab, Dortmund

15.00 – 15.15

Discussion

15.15 – 15.45

Break

15.45 – 17.15

**Session IV: The Future of Fibrosis Treatment:
New Targets and Translational Advances**

Chairs: Thomas Geiser, Bern

15.45 – 16.15

The Future of Pulmonary Fibrosis Treatment:
New Strategies and Innovations, *Manuela Funke, Bern*

16.15 – 16.45

Bridging Pathophysiology and Therapy:
The Future of Liver Fibrosis Treatment,
Jordi Gracia Sancho, Barcelona & Bern

16.45 – 17.15

The Role of B-Cells in Fibrosis, *Britta Maurer, Bern*

17.15 – 17.30

Discussion

17.30 – 18.00

Wrap Up,
*Annalisa Berzigotti, Bern; Thomas Geiser, Bern;
Britta Maurer, Bern*

From 17.45

Apéro

Scientific Committee:

Prof. Dr. Sabina Guler, Department of Pneumology, University Hospital Bern, Switzerland, Sabina.guler@insel.ch

Dr. Mirjam Kolev, Department of Hepatology, University Hospital Bern, Switzerland, Mirjam.kolev@insel.ch

PD Dr. Florian Kollert, Department of Rheumatology, University Hospital Basel, Switzerland, Florian.kollert@usb.ch

Dr. Adela-Cristina Sarbu, Department of Rheumatology, University Hospital Bern, Switzerland, adela-cristina.sarbu@insel.ch

Accreditation:

SGG/SSG 2 CMEs, SGP/SSP 7 CMEs, SGR/SSR 7 CMEs


Main Sponsor:



Organiser: endresprojects

Co-Sponsor:





1 Felix Frey Auditorium, SITEM

2 Train Station Bern

Faculty:

Prof. Dr. Annalisa Berzigotti, Department of Hepatology, University Hospital Bern, Switzerland
 Annalisa.berzigotti@insel.ch

Prof. Dr. Christopher Buckley, Kennedy Institute of Rheumatology, Oxford, UK
 christopher.buckley@ndorms.ox.ac.uk

Prof. Dr. Oliver Distler, Department of Rheumatology, University Hospital Zurich, Switzerland,
 oliver.distler@usz.ch

Prof. Dr. Thomas Dörner, Department of Rheumatology and Immunology, University Hospital Berlin, Germany, thomas.doerner@charite.de

PD Dr. Muriel Elhai, Department of Rheumatology, University Hospital Zurich, Switzerland
 muriel.elhai@usz.ch

Dr. Trine Folseraas, Section of Gastroenterology, University Hospital Oslo, Norway,
 trine.folseraas@medisin.uio.no

Prof. Dr. Manuela Funke-Chambour, Department of Pneumology, University Hospital Bern, Switzerland,
 manuela.funke-chambour@insel.ch

Prof. Dr. Thomas Geiser, Department of Pneumology, University Hospital Bern, Switzerland,
 thomas.geiser@insel.ch

Prof. Dr. Ahmed Ghallab, Department of Intravital Toxicology Leibniz Research Centre for Working Environment and Human Factors (IfAdo), Dortmund, Germany, Ghallab@ifado.de

MSc PhD FAASLD Jordi Gracia-Sancho, Head, Liver Vascular Biology Lab IDIBAPS, Hospital Clinic de Barcelona and Associate Researcher, Hepatology, Inselspital, University of Berne, JGRACIA@reerca.clinic.cat

Prof. Dr. Diego Kyburz, Department of Rheumatology, University Hospital Basel,
 diego.kyburz@usb.ch

Prof. Dr. Michael Kreuter, Department of Pneumology, University Hospital Mainz, Germany,
 kreuterm@uni-mainz.de

Prof. Dr. Sara Lemoine, Department of Rare Diseases, Hospital Saint-Antoine, Paris, France,
 sara.lemoine@aphp.fr

Prof. Dr. Britta Maurer, Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, britta.maurer@insel.ch


Prof. Dr. Christopher Ryerson, UBC Division of Respiratory Medicine, Vancouver, Canada,
 chris.ryerson@hli.ubc.ca

Prof. Dr. nat. phil. Nasser Semmo, Department of Hepatology, University Hospital Bern, Switzerland,
 Nasser.Semmo@insel.ch

PD Dr. Guido Stirnimann, Department of Hepatology, University Hospital Bern, Switzerland,
 guido.stirnimann@insel.ch

Prof. Dr. Augusto Vaglio, Department of Nephrology, University Hospital of Parma, Italy,
 augusto.vaglio@virgilio.it

Prof. Dr. Uli Walker, Department of Rheumatology, University Hospital Basel, Switzerland,
 ulrich.walker@usb.ch



Innovation in antifibrotic therapy

Lixudebart is an investigational Claudin-1 monoclonal antibody with disease modifying, pan-organ antifibrotic potential.

Clinical trials

Phase 2 - Recruiting

ANCA-associated vasculitis with renal involvement (RPGN) - [NCT06047171](#)

Phase 1b - Completed

Advanced liver fibrosis - [NCT05939947](#)

Phase 1 - Completed

Healthy volunteers

Learn more: www.alentis.ch/lixudebart

Lixudebart is investigational only and has not yet been approved for marketing by any regulatory authority. No representation is made as to the safety or effectiveness of lixudebart in the indications for which it is being studied.